Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer

Annals of Oncology

Volumn 13, Issue 2, 2002, Pages 229-236

  Strumberg, D ^a   Brugge S ^a   Korn, M W ^a   Koeppen, S ^b   Ranft, J ^b   Scheiber, G ^b   Reiners, C ^b   Muckel C ^b   Seeber, S ^a   Scheulen, M E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cardiovascular risk; Chemotherapy; Cisplatin; Long term toxicity; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; BLEOMYCIN; CHOLESTEROL; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IFOSFAMIDE; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; SEX HORMONE; TECHNETIUM 99M; TESTOSTERONE; TRIACYLGLYCEROL; VINBLASTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INTOXICATION; EVALUATION; EVOKED OTOACOUSTIC EMISSION; FOLLITROPIN BLOOD LEVEL; GONADAL DISEASE; HEARING DISORDER; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; LUNG TOXICITY; LUTEINIZING HORMONE BLOOD LEVEL; LYMPH NODE DISSECTION; MALE; METASTASIS; MICROCIRCULATION; MICROSCOPY; MORBIDITY; NEUROPATHY; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OBESITY; OTOTOXICITY; POLYNEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PRESSURE; CISPLATIN; FERTILITY; FOLLICLE STIMULATING HORMONE; HEARING; HEART; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; TESTICULAR NEOPLASMS;

EID: 0036299690     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf058     Document Type: Article

References (50)

1. Increase in testicular cancer incidence in six European countries: A birth cohort phenomenon
2. Treatment of testicular tumours based on risk factors
3. Guidelines for the diagnosis and therapy of testicular cancer and new developments
4. Testicular cancer: What's new in staging, prognosis, and therapy
5. Treatment of disseminated non-seminomatous testicular cancer: The European experience
6. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
7. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
8. Report on the International Workshop on Staging and Treatment of Testicular Cancer
9. Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cisdichlorodiammineplatinum (II) in non-seminomatous testicular cancer. I. Results of a prospective randomized phase III study disseminated disease (stage IV) (author's transl)
10. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
11. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991
12. The symptom check-list, SCL-90-R: Its use and characteristics in chronic pain patients
13. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
14. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide
15. Application of the single-breath method of total lung capacity measurement to the calculation of the carbon monoxide diffusing capacity
16. The effect of anemia on pulmonary diffusing capacity with derivation of a correction equation
17. Guidelines for exercise testing
18. Normal values in equilibrium radionuclide ventriculography. Results of a multicenter study
19. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy
20. Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5-FU
21. Otoacoustic emissions (TEOAE and DPOAE) after middle ear operation
22. Plasma endothelin concentration during cold provocation in primary Raynaud's syndrome
23. Vital capillary-microscopic findings in normal subjects, patients with peripheral arterial occlusive disease (Fontaine II to IV) and patients with thrombangiitis obliterans
24. Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs
25. The Prospective Cardiovascular Munster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease
26. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
27. Evaluation of long-term toxicity after chemotherapy for testicular cancer
28. Endocrinological late effects after chemotherapy for testicular cancer
29. Does chemotherapy for testicular cancer increase cardiovascular risk?
30. The risk of early thromboembolic complications (TEC) is significantly increased in patients with germ-cell tumors (GCT) and can be predicted according to the patient's weight and LDH level
31. Long-term sequelae of treatment for testicular germ cell tumours
32. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer
33. Preservation of antegrade ejaculation in retroperitoneal lymphadenectomy due to residual masses after primary chemotherapy for testicular carcinoma
34. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): A preliminary report
35. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
36. Neurotoxicity of antineoplastic drugs
37. Peripheral sensory neuropathy and cisplatin chemotherapy
38. Prospective nerve conduction studies in cisplatin therapy
39. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer
40. Toxicity of treatment of germ cell tumors
41. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity
42. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives
43. Risk factors for ototoxicity due to cisplatin
44. Interaction of cisplatin and noise on the peripheral auditory system
45. Hearing loss-risk factor for cisplatin ototoxicity?
46. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients
47. Long-term effects of chemotherapy in patients with testicular cancer
48. Therapy-related related malignancies following treatment of germ cell cancer
49. Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols
50. Secondary tumours following etoposide containing therapy for germ cell cancer